A5051900899- Gastric Cancer Management and Outcomes
- Colorectal Cancer Treatments and Studies
- Genetic factors in colorectal cancer
- Cancer Immunotherapy and Biomarkers
- Metastasis and carcinoma case studies
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Gastrointestinal Tumor Research and Treatment
- Cancer-related molecular mechanisms research
- BRCA gene mutations in cancer
- Immune Cell Function and Interaction
- Inflammatory mediators and NSAID effects
- Viral-associated cancers and disorders
- Financial Crisis of the 21st Century
- Gastrointestinal disorders and treatments
- Colorectal Cancer Screening and Detection
- Male Breast Health Studies
- Genomic variations and chromosomal abnormalities
Amsterdam University Medical Centers
2021-2024
Cancer Center Amsterdam
2023
Vrije Universiteit Amsterdam
2023
The Netherlands Cancer Institute
2015-2018
University Medical Center Utrecht
2018
Oncode Institute
2015
Epstein-Barr virus positivity (EBV+) and microsatellite instability (MSI-high) are positive prognostic factors for survival in resectable gastric cancer (GC). However, benefit of perioperative treatment patients with MSI-high tumors remains topic discussion. Here, we present the clinicopathological outcomes EBV+, MSI-high, EBV-/MSS GCs who received either surgery only or treatment.EBV MSI status were determined on tumor samples collected from 447 treated D1/D2 trial, 451 perioperatively...
Purpose Patients with metastatic colorectal cancer (mCRC) have limited benefit from the addition of bevacizumab to standard chemotherapy. However, a subset probably benefits substantially, highlighting an unmet clinical need for biomarker response bevacizumab. Previously, we demonstrated that losses chromosomes 5q34, 17q12, and 18q11.2-q12.1 had significant correlation progression-free survival (PFS) in patients mCRC treated CAIRO2 trial but not who did receive CAIRO trial. This study was...
Tumor-infiltrating lymphocytes are associated with the survival of gastric cancer patients. T-cell densities in tumor and its periphery were previously identified as prognostic markers for resectable cancer. Immunohistochemistry 5 markers, CD3, CD45RO, CD8, FOXP3, granzyme B was performed on serial sections N = 251 surgical resection specimens patients treated surgery only D1/D2 trial. Positive T cells digitally quantified into tiles 0.25 mm2 across 3 regions: center (TC), inner invasive...
Genomic aberrations can be used to subtype breast cancer. In this study, we investigated DNA copy number (CN) profiles of 69 cases male cancer (MBC) by array comparative genomic hybridization (aCGH) detect recurrent gains and losses in comparison with female cancers (FBC). Further, classified these as BRCA1‐like, BRCA2‐like or non‐BRCA‐like using previous classifiers derived from FBC, correlated pathological characteristics. We observed large CN on chromosome arms 1q, 5p, 8q, 10p, 16p, 17q,...
Abstract Background The Cancer Genome Atlas (TCGA) recognizes four molecular subgroups of gastric cancer: Epstein-Barr virus (EBV) positive, microsatellite instable (MSI), genomically stable (GS), and chromosomal (CIN). Since a GS/CIN classifier is lacking, alternative markers such as Lauren’s histopathology or CDH1/p53 immunohistochemistry are commonly applied. Here we compared survival cancer determined by methods. Methods 309 EBV negative tumors were included from the Dutch D1/D2 trial...
Abstract Background In the era of individualized gastric cancer (GC) treatment, accurate determination histological subtype becomes increasingly relevant. As yet, it is unclear whether preoperative chemotherapy may affect subtype. The aim this study was to assess concordance in between pretreatment biopsies and surgical resection specimens before after introduction perioperative treatment. Methods Histological centrally determined paired GC patients treated with either surgery alone (SA)...
Abstract Introduction: Most patients with metastatic colorectal cancer (mCRC) have a limited benefit from the addition of bevacizumab to standard combination chemotherapy. However, subset benefits substantially, highlighting an unmet clinical need for predictive biomarker response bevacizumab. Previously, we demonstrated that losses in chromosome 5q34, 17q12 and 18q12.1-21.1 significant correlation progression free survival (PFS) treated with, but not without These data warrant extensive...
Abstract Introduction: In gastric cancer, studies of tumor infiltrating lymphocytes as a prognostic biomarker show contradictory results. These results may be caused by use variable immunohistochemistry (IHC) quantification techniques, different marker selections and particularly inconsistency in the evaluated regions. To overcome these issues, we performed comprehensive digital image analysis 5 immune cell markers for their value cohort cancer patients who were treated with surgery only...
Abstract Background: Epstein-Barr virus positivity (EBV+) and microsatellite instability (MSI-high) have been shown to be positive prognostic factors for long term survival in resectable gastric cancer (GC) several studies. However, the benefit of perioperative treatment patients with MSI-high tumors remains topic discussion. Here, we present clinicopathological outcome EBV+ GCs treated surgery only Dutch D1/D2 trial, chemotherapy or chemoradiotherapy after preoperative CRITICS trial....